TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Shin Nippon Biomedical Laboratories, Ltd. ( (JP:2395) ).
SNBL’s subsidiary, SNLD, will present findings from a Phase II clinical study on TR-012001, a nasal levodopa therapy for Parkinson’s Disease, at the American Academy of Neurology 2025 Annual Meeting. This development highlights SNBL’s commitment to innovative treatments for PD, potentially improving management of OFF episodes and enhancing patient quality of life.
More about Shin Nippon Biomedical Laboratories, Ltd.
Shin Nippon Biomedical Laboratories, Ltd. (SNBL) operates in the biomedical industry, focusing on the development of novel therapies for central nervous system diseases, particularly Parkinson’s Disease (PD). A key subsidiary, SNLD, specializes in intranasal drug delivery platforms to advance treatments for PD and other neurological disorders.
YTD Price Performance: -7.73%
Average Trading Volume: 308,625
Technical Sentiment Signal: Hold
Current Market Cap: Yen64.07B
For detailed information about 2395 stock, go to TipRanks’ Stock Analysis page.